435 related articles for article (PubMed ID: 16178819)
21. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1).
He SM; Li R; Kanwar JR; Zhou SF
Curr Med Chem; 2011; 18(3):439-81. PubMed ID: 21143116
[TBL] [Abstract][Full Text] [Related]
22. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
Budworth J; Davies R; Malkhandi J; Gant TW; Ferry DR; Gescher A
Br J Cancer; 1996 May; 73(9):1063-8. PubMed ID: 8624264
[TBL] [Abstract][Full Text] [Related]
23. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR).
Teodori E; Dei S; Martelli C; Scapecchi S
Curr Top Med Chem; 2010; 10(17):1715-31. PubMed ID: 20645921
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Shukla S; Robey RW; Bates SE; Ambudkar SV
Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
[TBL] [Abstract][Full Text] [Related]
25. N-(p-azido-3-[125I]iodophenethyl)spiperone binds to specific regions of P-glycoprotein and another multidrug binding protein, spiperophilin, in human neuroblastoma cells.
Safa AR; Agresti M; Bryk D; Tamai I
Biochemistry; 1994 Jan; 33(1):256-65. PubMed ID: 7904476
[TBL] [Abstract][Full Text] [Related]
26. Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide.
Gupta KP; Ward NE; Gravitt KR; Bergman PJ; O'Brian CA
J Biol Chem; 1996 Jan; 271(4):2102-11. PubMed ID: 8567666
[TBL] [Abstract][Full Text] [Related]
27. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
28. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
29. Characterization of two pharmacophores on the multidrug transporter P-glycoprotein.
Garrigues A; Loiseau N; Delaforge M; Ferté J; Garrigos M; André F; Orlowski S
Mol Pharmacol; 2002 Dec; 62(6):1288-98. PubMed ID: 12435795
[TBL] [Abstract][Full Text] [Related]
30. Computational models for identifying potential P-glycoprotein substrates and inhibitors.
Crivori P; Reinach B; Pezzetta D; Poggesi I
Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367
[TBL] [Abstract][Full Text] [Related]
31. Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer.
Halder J; Pradhan D; Kar B; Ghosh G; Rath G
Nanomedicine; 2022 Feb; 40():102494. PubMed ID: 34775061
[TBL] [Abstract][Full Text] [Related]
32. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp).
Zhang H; Xu H; Ashby CR; Assaraf YG; Chen ZS; Liu HM
Med Res Rev; 2021 Jan; 41(1):525-555. PubMed ID: 33047304
[TBL] [Abstract][Full Text] [Related]
33. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.
Gekeler V; Boer R; Uberall F; Ise W; Schubert C; Utz I; Hofmann J; Sanders KH; Schächtele C; Klemm K; Grunicke H
Br J Cancer; 1996 Sep; 74(6):897-905. PubMed ID: 8826855
[TBL] [Abstract][Full Text] [Related]
34. The P-glycoprotein multidrug transporter.
Fardel O; Lecureur V; Guillouzo A
Gen Pharmacol; 1996 Dec; 27(8):1283-91. PubMed ID: 9304397
[TBL] [Abstract][Full Text] [Related]
35. P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships.
Di Pietro A; Dayan G; Conseil G; Steinfels E; Krell T; Trompier D; Baubichon-Cortay H; Jault J
Braz J Med Biol Res; 1999 Aug; 32(8):925-39. PubMed ID: 10454753
[TBL] [Abstract][Full Text] [Related]
36. Biophysical aspects of P-glycoprotein-mediated multidrug resistance.
Wadkins RM; Roepe PD
Int Rev Cytol; 1997; 171():121-65. PubMed ID: 9066127
[TBL] [Abstract][Full Text] [Related]
37. Rack1 mediates Src binding to drug transporter P-glycoprotein and modulates its activity through regulating Caveolin-1 phosphorylation in breast cancer cells.
Fan Y; Si W; Ji W; Wang Z; Gao Z; Tian R; Song W; Zhang H; Niu R; Zhang F
Cell Death Dis; 2019 May; 10(6):394. PubMed ID: 31113938
[TBL] [Abstract][Full Text] [Related]
38. An N-myristoylated protein kinase C-alpha pseudosubstrate peptide that functions as a multidrug resistance reversal agent in human breast cancer cells is not a P-glycoprotein substrate.
Bergman PJ; Gravitt KR; O'Brian CA
Cancer Chemother Pharmacol; 1997; 40(5):453-6. PubMed ID: 9272125
[TBL] [Abstract][Full Text] [Related]
39. Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators.
Krishna R; Mayer LD
Curr Med Chem Anticancer Agents; 2001 Aug; 1(2):163-74. PubMed ID: 12678765
[TBL] [Abstract][Full Text] [Related]
40. Multidrug resistance transporters and modulation.
Tan B; Piwnica-Worms D; Ratner L
Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
